
## Annalisa Paviglianiti

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4427812/publications.pdf Version: 2024-02-01



| #  | Article   | IF  | CITATIONS |
|----|---|-----|-----------|
| 1  | COVID-19 outcomes in patients with hematologic disease. Bone Marrow Transplantation, 2020, 55, 2180-2184.   | 2.4 | 138       |
| 2  | Allele-level HLA matching for umbilical cord blood transplantation for non-malignant diseases in children: a retrospective analysis. Lancet Haematology,the, 2017, 4, e325-e333.  | 4.6 | 72        |
| 3  | Early Cardiac Toxicity Associated With Post-Transplant Cyclophosphamide in Allogeneic Stem Cell<br>Transplantation. JACC: CardioOncology, 2021, 3, 250-259.   | 4.0 | 48        |
| 4  | Early and late outcomes after cord blood transplantation for pediatric patients with inherited leukodystrophies. Blood Advances, 2018, 2, 49-60.  | 5.2 | 45        |
| 5  | Thiotepa, Busulfan, and Fludarabine Conditioning Regimen in T Cell-Replete HLA-Haploidentical<br>Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25,<br>1407-1415.  | 2.0 | 42        |
| 6  | Impact of <scp>HLA</scp> in cord blood transplantation outcomes. Hla, 2016, 87, 413-421.  | 0.6 | 31        |
| 7  | Hematopoietic stem cell transplantation with unrelated cord blood or haploidentical donor grafts<br>in adult patients with secondary acute myeloid leukemia, a comparative study from Eurocord and the<br>ALWP EBMT. Bone Marrow Transplantation, 2019, 54, 1987-1994.  | 2.4 | 25        |
| 8  | Low Body Mass Index Is Associated with Increased Risk of Acute GVHD after Umbilical Cord Blood<br>Transplantation in Children and Young Adults with Acute Leukemia: A Study on Behalf of Eurocord<br>and the EBMT Pediatric Disease Working Party. Biology of Blood and Marrow Transplantation, 2018,<br>24, 799-805.   | 2.0 | 22        |
| 9  | Outcomes after Unrelated Umbilical Cord Blood Transplantation for Children with Osteopetrosis.<br>Biology of Blood and Marrow Transplantation, 2016, 22, 1997-2002.   | 2.0 | 17        |
| 10 | Impact of cyclosporine A concentration on acute graftâ€vsâ€host disease incidence after haploidentical<br>hematopoietic cell transplantation. European Journal of Haematology, 2019, 103, 10-17.  | 2.2 | 17        |
| 11 | Outcomes of unrelated cord blood transplantation in patients with multiple myeloma: a survey on<br>behalf of Eurocord, the Cord Blood Committee of Cellular Therapy and Immunobiology Working<br>Party, and the Chronic Leukemia Working Party of the EBMT. Haematologica, 2016, 101, 1120-1127.  | 3.5 | 16        |
| 12 | Endothelial and Circulating Progenitor Cells in Hematological Diseases and Allogeneic Hematopoietic Stem Cell Transplantation. Current Medicinal Chemistry, 2018, 25, 4535-4544.  | 2.4 | 12        |
| 13 | Cord Blood Unit Dominance Analysis and Effect of the Winning Unit on Outcomes after Double-Unit<br>Umbilical Cord Blood Transplantation in Adults with Acute Leukemia: A Retrospective Study on Behalf<br>of Eurocord, the Cord Blood Committee of Cellular Therapy, Immunobiology Working Party, and the<br>Acute Leukemia Working Party of the European Croup for Blood and Marrow Transplantation. | 2.0 | 11        |
| 14 | Biology of Blood and Marrow Transplantation, 2018, 24, 1657-1663.<br>Outcomes of Advanced Hodgkin Lymphoma after Umbilical Cord Blood Transplantation: A Eurocord<br>and EBMT Lymphoma and Cellular Therapy & Immunobiology Working Party Study. Biology of<br>Blood and Marrow Transplantation, 2018, 24, 2265-2270.   | 2.0 | 10        |
| 15 | Risk factors affecting outcome of unrelated cord blood transplantation for children with familial haemophagocytic lymphohistiocytosis. British Journal of Haematology, 2019, 184, 397-404.  | 2.5 | 10        |
| 16 | Tolerability and Efficacy of Treatment With Azacytidine as Prophylactic or Preemptive Therapy for<br>Myeloid Neoplasms After Allogeneic Stem Cell Transplantation. Clinical Lymphoma, Myeloma and<br>Leukemia, 2020, 20, 377-382.   | 0.4 | 10        |
| 17 | Evaluation of a disease risk index for adult patients undergoing umbilical cord blood transplantation for haematological malignancies. British Journal of Haematology, 2017, 179, 790-801.  | 2.5 | 9         |
| 18 | Highâ€dose postâ€ŧransplant cyclophosphamide impairs γδTâ€cell reconstitution after haploidentical<br>haematopoietic stem cell transplantation using lowâ€dose antithymocyte globulin and peripheral blood<br>stem cell graft. Clinical and Translational Immunology, 2020, 9, e1171.   | 3.8 | 9         |

| #  | Article  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Thiotepa-busulfan-fludarabine as a conditioning regimen for patients with myelofibrosis undergoing<br>allogeneic hematopoietic transplantation: a single center experience. Leukemia and Lymphoma, 2021, 62,<br>419-427.   | 1.3 | 9         |
| 20 | Family cord blood banking for sickle cell disease: a twenty-year experience in two dedicated public cord blood banks. Haematologica, 2017, 102, 976-983.   | 3.5 | 8         |
| 21 | Extracorporeal photopheresis as first-line strategy in the treatment of acute graft-versus-host<br>disease after hematopoietic stem cell transplantation: A single-center experience. Cytotherapy, 2020,<br>22, 445-449.   | 0.7 | 8         |
| 22 | Multiple Myeloma Outpatient Transplant Program in the Era of Novel Agents: State-of-the-Art.<br>Frontiers in Oncology, 2020, 10, 592487.   | 2.8 | 7         |
| 23 | Gemtuzumab Ozogamicin Combined With Intensive Chemotherapy in Patients With Acute Myeloid<br>Leukemia Relapsing After Allogenic Stem Cell Transplantation. Clinical Lymphoma, Myeloma and<br>Leukemia, 2020, 20, 791-796.  | 0.4 | 6         |
| 24 | The Burden in Caregivers of Multiple Myeloma Patients Undergoing Outpatient Autologous Stem-Cell<br>Transplantation Compared to Inpatient Transplantation. Clinical Lymphoma, Myeloma and Leukemia,<br>2021, 21, e402-e409.  | 0.4 | 4         |
| 25 | Comparison of mycophenolate mofetil and calcineurin inhibitor versus calcineurin inhibitor-based<br>graft-versus-host-disease prophylaxis for matched unrelated donor transplant in acute myeloid<br>leukemia. A study from the ALWP of the EBMT. Bone Marrow Transplantation, 2021, 56, 1077-1085.                              | 2.4 | 4         |
| 26 | An update on B-cell maturation antigen-targeted therapies in Multiple Myeloma. Expert Opinion on<br>Biological Therapy, 2021, 21, 1025-1034.   | 3.1 | 4         |
| 27 | Netupitant/palonosetron without dexamethasone for preventing nausea and vomiting in patients with multiple myeloma receiving high-dose melphalan for autologous stem cell transplantation: a single-center experience. Supportive Care in Cancer, 2022, 30, 585-591.   | 2.2 | 4         |
| 28 | A Case of Transplantation-Associated Thrombotic Microangiopathy with Cardiac Involvement<br>Successfully Treated with Plasma Exchange. Indian Journal of Hematology and Blood Transfusion,<br>2014, 30, 369-371.   | 0.6 | 3         |
| 29 | Allogenic stem cell transplantation in multiple myeloma: dead or alive and kicking?. Panminerva<br>Medica, 2021, 62, 234-243.  | 0.8 | 3         |
| 30 | <p>A Review on the Impact of Body Mass Index on Outcomes in Pediatric Leukemia</p> .<br>Journal of Blood Medicine, 2020, Volume 11, 205-212.   | 1.7 | 2         |
| 31 | Selecting Double Cord Blood Units for Adults with Hematological Malignancies: Impact of ABO, HLA<br>and Cell Dose on Outcomes after Double Cord Blood Transplants a CBC-Cellular Therapy &<br>Immunobiology Working Party, EBMT and Eurocord Study. Blood, 2015, 126, 3214-3214.   | 1.4 | 1         |
| 32 | Endocrine and Metabolic Disorders After Hematopoietic Stem Cell Transplantation Annalisa<br>Paviglianiti Metabolic Diseases in Hematology. Turkish Journal of Haematology, 2020, 37, 111-115.  | 0.5 | 1         |
| 33 | Granisetron transdermal system and dexamethasone for the prevention of nausea and vomiting in multiple myeloma patients receiving chemo-mobilization: An observational real-world study of effectiveness and safety. Transfusion and Apheresis Science, 2020, 59, 102911.  | 1.0 | Ο         |
| 34 | Calcineurin Inhibitor Alone or in Combination with Mycophenolate Mofetil for<br>Graft-Versus-Host-Disease Prophylaxis in Patients with Acute Myeloid Leukemia Undergoing<br>Transplantation from Matched Unrelated Donors: A Study from the ALWP of the EBMT. Biology of<br>Blood and Marrow Transplantation, 2020, 26, S56-S57. | 2.0 | 0         |
| 35 | Stable pulmonary function after haploidentical stem cell transplantation with post-transplant cyclophosphamide: a single center experience. Leukemia and Lymphoma, 2022, 63, 443-449.  | 1.3 | 0         |
| 36 | Outcomes of Unrelated Cord Blood Transplantation in Patients with Multiple Myeloma a Eurocord,<br>CBC-Cellular Therapy & Immunobiology Working Party and Chronic Malignancies Working<br>Party-EBMT Study. Blood, 2015, 126, 3203-3203.  | 1.4 | 0         |

| #  | Article   | lF  | CITATIONS |
|----|---|-----|-----------|
| 37 | Impact of Refined Disease Risk Index after Single and Double Umbilical Cord Blood Transplantation in<br>Adults with Hematological Malignancies. Blood, 2016, 128, 3484-3484.  | 1.4 | 0         |
| 38 | Comparison of Mycophenolate Mofetil and a Calcineurin Inhibitor Versus Calcineurin Inhibitor Based<br>Graft-Versus-Host-Disease Prophylaxis for Matched Unrelated Donor Transplant for Acute Myeloid<br>Leukemia. a Study from the ALWP of the EBMT. Blood, 2019, 134, 4548-4548. | 1.4 | 0         |
| 39 | Stable Pulmonary Function after Haploidentical Stem Cell Transplantation with Post-Transplant<br>Cyclophosphamide: A Single Center Experience. Blood, 2020, 136, 30-30.   | 1.4 | 0         |